SCHEMBL14723315

SCHEMBL14723315

Fc1cc2nc[nH]c2cc1Br

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.56
ALDH1A1 P00352 2/20 0.48
KDM4E B2RXH2 2/20 0.48
APEX1 P27695 1/20 0.48
RECQL P46063 1/20 0.48
BLM P54132 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
PRKCI P41743 1/20 0.41
MEN1 O00255 1/20 0.41
PRNP P04156 1/20 0.41
HPGD P15428 1/20 0.41
HTT P42858 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
RAD52 P43351 1/20 0.40
QPCT Q16769 3/20 0.39
CHRNB2 P17787 1/20 0.39
CHRNA4 P43681 1/20 0.39
CDK1 P06493 3/20 0.38
MMP12 P39900 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31150482 1.00 MAPT (0.56) MAPTALDH1A1KDM4EAPEX1RECQL
SCHEMBL3044280 0.92 MAPT (0.61) MAPTALDH1A1KDM4EAPEX1RECQL
SCHEMBL31153163 0.92 MAPT (0.61) MAPTALDH1A1KDM4EAPEX1RECQL
SCHEMBL1266091 0.83 MAPT (0.70) MAPTALDH1A1KDM4EAPEX1RECQL
SCHEMBL8370769 0.83 MAPT (0.56) MAPTALDH1A1KDM4EAPEX1RECQL
Benzene SCHEMBL28968025 0.79 MAPT (0.52) MAPTALDH1A1KDM4EAPEX1RECQL
SCHEMBL23124230 0.76 MAPT (0.61) MAPTALDH1A1KDM4EAPEX1RECQL
SCHEMBL13373332 0.76 MAPT (0.48) MAPTALDH1A1KDM4EAPEX1RECQL
SCHEMBL31444162 0.76 MAPT (0.48) MAPTALDH1A1KDM4EAPEX1RECQL
SCHEMBL30363506 0.76 MAPT (0.85) MAPTALDH1A1KDM4EAPEX1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4466258-A1 NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2024-11-27 EP disclosed
WO-2023139085-A1 NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2023-07-27 WO disclosed
EP-3159335-B1 NOVEL HETEROCYCLIC COMPOUND DAE WOONG PHARMA (KR) 2020-04-29 EP disclosed
US-10081634-B2 Heterocyclic compound DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2018-09-25 US disclosed
EP-3159335-A2 NOVEL HETEROCYCLIC COMPOUND Daewoong Pharmaceutical Co., Ltd. (KR) 2017-04-26 EP disclosed
US-20170088551-A1 NOVEL HETEROCYCLIC COMPOUND Daewoong Pharmaceutical., Ltd. (KR) 2017-03-30 US disclosed
EP-2748159-A1 SERINE/THREONINE PAK1 INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2014-07-02 EP disclosed
US-8637537-B2 Serine/threonine kinase inhibitors GENENTECH, INC. (US) 2014-01-28 US disclosed
US-20130225620-A1 SERINE/THREONINE KINASE INHIBITORS GENENTECH, INC. (US) 2013-08-29 US disclosed
WO-2013026914-A1 SERINE/THREONINE PAK1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2013-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225620-A1 SERINE/THREONINE KINASE INHIBITORS PAK1, AKT1, RB1 MAPT 2138/4885ALDH1A1 2874/4885KDM4E 2561/4885
US-10081634-B2 Heterocyclic compound AARS1, NSUN3, RNASE1 MAPT 3681/4885ALDH1A1 1349/4885KDM4E 3488/4885
US-20170088551-A1 NOVEL HETEROCYCLIC COMPOUND AARS1, TARBP1, NSUN3 MAPT 3773/4885ALDH1A1 2054/4885KDM4E 3544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.